Cost-Effectiveness of Statin Therapy by Age Risk Model Calculator

Clinical calculation support · Verify results before clinical use

Model inputs

Adjust the assumptions to explore a simplified primary-prevention statin cost-effectiveness scenario.

Recorded for context; this simplified calculation does not use age to alter risk or treatment effect.
Recorded for context; sex does not modify the model equations.
Enter a validated estimate as a percentage, e.g. 7.5 for 7.5%.
This is descriptive only; the assumed RRR below drives the calculation.
Enter a scenario assumption supported by the evidence relevant to the population and endpoint.
Simplifies a potentially time-dependent event-related health loss to one input.
Treated as a cumulative excess probability over the selected horizon, not an annual rate.
The 10-year risk is extrapolated to this horizon using a constant-hazard assumption.
Reset inputs

How to interpret this model

This is a transparent, simplified scenario calculator for exploring how baseline cardiovascular risk, assumed treatment effect, costs, quality-adjusted life-years (QALYs), and a willingness-to-pay (WTP) threshold affect estimated cost-effectiveness.

Calculation framework

  • Horizon-adjusted risk = 1 − (1 − 10-year risk)horizon/10, assuming a constant hazard.
  • Absolute risk reduction (ARR) = horizon-adjusted risk × assumed relative risk reduction (RRR).
  • Net QALYs = QALYs gained from avoided events − pill disutility − diabetes-related QALY loss.
  • Net costs = drug costs + monitoring costs − estimated costs avoided.
  • Net monetary benefit (NMB) = (WTP × net QALYs) − net costs; NMB ≥ 0 is classified as cost-effective in this scenario.

Important model limitations

  • This is not a validated clinical prediction tool or a full health-economic model. It does not model competing risks, adherence, discounting, recurrent events, survival, or uncertainty distributions.
  • Age and sex are recorded but do not affect the equations; risk must be estimated externally using an appropriate validated tool.
  • The horizon extrapolation, event-related QALY loss, diabetes-related disutility, and cost offsets are simplifying assumptions. They require local validation before research, policy, or clinical use.
  • Results can be misleading if the input RRR, risk estimate, costs, or utility assumptions do not match the population, endpoint, and time horizon.

Evidence and references

Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015;314(2):142–150.

https://doi.org/10.1001/jama.2015.6822

Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.

https://doi.org/10.1016/S0140-6736(12)60367-5

US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. 2022.

Official recommendation

These sources provide context for statin benefit and economic modelling. They do not validate every equation or default value in this simplified calculator.

Clinical and economic disclaimer: For educational and exploratory use only. This output should not be used alone to make treatment decisions or to claim a formal cost-effectiveness result. Use locally relevant costs, validated risk estimation, evidence-based treatment effects, appropriate time-dependent utilities, discounting, and sensitivity analyses for a formal health-economic evaluation.